빈혈 치료 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the anemia treatment market size was valued at USD 12.31 billion in 2025 and estimated to grow from USD 13.13 billion in 2026 to reach USD 18.09 billion by 2031, at a CAGR of 6.65% during the forecast period (2026-2031).

This report is Segmented by Disease Type (Iron Deficiency Anemia, CKD Anemia, Sickle Cell Anemia, Aplastic Anemia, Thalassemia and Other Rare Anemias), Therapy Class (Oral Iron Supplements, Intravenous Iron, Esas, Iron Chelators, and More), Route of Administration (Oral and Injectable), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Anemia Treatment Market Trends and Insights

Escalating Worldwide Incidence and Earlier Diagnosis of Anemia

The combined effects of demographic change, improved screening, and AI-supported imaging uncover previously hidden cases across populations. . The World Health Organization reports that 29.9% of women aged 15-49 and 39.8% of children aged 6-59 months suffered from anemia globally, with the African region showing the highest prevalence at 60.2% among children under five. Smartphone-based tests that deliver hemoglobin values in under one minute widen access and help providers intervene sooner, increasing patient volumes in the anemia treatment market.

Growing Prevalence of Comorbid Chronic Diseases

Chronic kidney disease, cancer, and inflammatory disorders each elevate anemia risk and require more complex interventions than iron replacement alone. The 2025 KDIGO guideline recognizes the need to combine ESAs and emerging HIF-PH inhibitors to manage renal anemia safely. As oncology treatment volumes rise, supportive anemia care preserves quality of life for up to 70% of patients receiving chemotherapy, supporting steady demand in the anemia treatment market.

ESA & Gene-Therapy Cost-Containment Pressures

Payers now require step-therapy, forcing oral iron trials ahead of intravenous options, while biosimilar ESAs chip away at branded pricing. Curative gene therapies face reimbursement hurdles given their high upfront cost, limiting access even where clinical value is clear. Payer policies increasingly emphasize step therapy requirements, mandating oral iron trials before approving expensive intravenous formulations, thereby delaying optimal treatment initiation. The emergence of biosimilar ESAs further pressures originator pricing while HIF-PH inhibitors face uncertainty regarding long-term cardiovascular safety profiles.

Other drivers and restraints analyzed in the detailed report include:

1. Regulatory Approvals and Pipeline Progress for Novel Therapeutic Classes
2. Government Nutrition Programs for Women of Reproductive Age
3. Safety Concerns (Thrombo-embolism, Iron Overload) Curb Use

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Iron deficiency anemia accounted for 44.68% of the anemia treatment market size in 2025, underlining its status as the widest clinical segment. High prevalence among women of child-bearing age and children ensures large-scale demand for low-cost iron therapy and supports volume-driven growth across both developed and emerging economies. Government procurement under mass supplementation schemes keeps standard iron products in steady circulation, maintaining leadership despite lower per-unit pricing.

Sickle cell anemia is projected to advance at an 8.15% CAGR, outpacing every other disease subtype within the anemia treatment market. Breakthrough therapies such as CASGEVY and related gene-editing candidates create premium subsegments that attract specialized funding and center-of-excellence models. Growing newborn screening in the United States and selected African countries further enlarges the addressable patient pool and accelerates diagnosis, steering attention toward curative rather than palliative care. The anemia treatment industry therefore sees value migration from high-volume, low-margin iron deficiency products to low-volume, high-margin gene therapies for hemoglobinopathies.

Complete Report Scope:

• By Disease Type
  • Iron Deficiency Anemia
  • CKD Anemia
  • Sickle Cell Anemia
  • Aplastic Anemia
  • Thalassemia
  • Other Rare Anemias
• By Therapy Class
  • Oral Iron Supplements
  • Intravenous Iron
  • ESAs
  • Iron Chelators
  • HIF-PH Inhibitors
  • Others
• By Route of Administration
  • Oral
  • Injectable
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 37.05% of total sales in 2025, reflecting early adoption of premium therapies and insurance frameworks that reimburse high-cost gene editing, ESA biologics, and injectable irons. Comprehensive newborn screening and precision-medicine programs bolster uptake across rare anemia segments. Payer scrutiny, however, caps ESA growth and encourages biosimilar use, shaping a value-oriented procurement environment that still rewards innovation when strong clinical outcomes are demonstrated.

Europe presents steady but more price-sensitive expansion. Harmonized regulatory reviews permit rapid biosimilar penetration, spreading access to established biologics while containing costs. Countries such as Germany and the United Kingdom have adopted pathway funding for CRISPR therapies, yet negotiate outcomes-based contracts to align high upfront payments with long-term clinical benefit. Iron chelation combinations receive acceptance after favorable safety and efficacy evidence, reinforcing diversified therapy mixes across national health services.

Asia Pacific is the fastest-growing region at 8.02% CAGR through 2031, driven by widening insurance coverage, rising chronic disease loads, and government-led nutrition drives. China's regulatory reforms speed approval of HIF-PH inhibitors, while domestic manufacturers scale generic IV iron, lowering average selling prices and boosting penetration. Smartphone-enabled diagnostics further lift test volumes, feeding prescription demand throughout the anemia treatment market.

1. Akebia Therapeutics
2. GlaxoSmithKline
3. Pfizer (incl. GBT)
4. Pieris Pharmaceuticals
5. Sanofi
6. Takeda Pharmaceuticals
7. Abbvie
8. Pharmacosmos
9. Covis Pharma (AMAG)
10. Amgen
11. CSL Vifor
12. Novartis
13. Johnson & Johnson
14. Roche
15. Biocon Biologics
16. Otsuka Pharma
17. CRISPR Therapeutics AG
18. Vertex Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Escalating worldwide incidence and earlier diagnosis of anemia
  • 4.2.2 Growing prevalence of comorbid chronic diseases
  • 4.2.3 Regulatory approvals and pipeline progress for novel therapeutic classes
  • 4.2.4 Government nutrition programs for women of reproductive age
  • 4.2.5 AI-enabled PoC hematology devices expanding diagnosis reach
  • 4.2.6 Precision-medicine advances in hematology
• 4.3 Market Restraints
  • 4.3.1 ESA & gene-therapy cost-containment pressures
  • 4.3.2 Safety concerns (thrombo-embolism, iron overload) curb use
  • 4.3.3 Cold-chain biologic supply bottlenecks in LMICs
  • 4.3.4 Low therapy adherence due to GI side-effects of orals
• 4.4 Regulatory Landscape
• 4.5 Pipeline Analysis
• 4.6 Porter's Five Forces Analysis
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitutes
  • 4.6.5 Intensity of Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Disease Type
  • 5.1.1 Iron Deficiency Anemia
  • 5.1.2 CKD Anemia
  • 5.1.3 Sickle Cell Anemia
  • 5.1.4 Aplastic Anemia
  • 5.1.5 Thalassemia
  • 5.1.6 Other Rare Anemias
• 5.2 By Therapy Class
  • 5.2.1 Oral Iron Supplements
  • 5.2.2 Intravenous Iron
  • 5.2.3 ESAs
  • 5.2.4 Iron Chelators
  • 5.2.5 HIF-PH Inhibitors
  • 5.2.6 Others
• 5.3 By Route of Administration
  • 5.3.1 Oral
  • 5.3.2 Injectable
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.4.1 Akebia Therapeutics
  • 6.4.2 GSK plc
  • 6.4.3 Pfizer (incl. GBT)
  • 6.4.4 Pieris Pharmaceuticals
  • 6.4.5 Sanofi
  • 6.4.6 Takeda
  • 6.4.7 AbbVie (Allergan)
  • 6.4.8 Pharmacosmos
  • 6.4.9 Covis Pharma (AMAG)
  • 6.4.10 Amgen
  • 6.4.11 CSL Vifor
  • 6.4.12 Novartis
  • 6.4.13 Johnson & Johnson (Janssen)
  • 6.4.14 Roche
  • 6.4.15 Biocon Biologics
  • 6.4.16 Otsuka Pharma
  • 6.4.17 CRISPR Therapeutics AG
  • 6.4.18 Vertex Pharmaceuticals

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment